Project Type(s):
Clinical Research
Prazosin, like many of our most effective treatments for PTSD, seems to be significantly more effective for some individuals than others. We have hypothesized that this is because prazosin works to compensate for increased noradrenergic signaling, which is a primary driver of symptoms in some, but not all, individuals with PTSD. If we could identify individuals where increased or inappropriate noradrenergic signaling is driving PTSD symptoms, it would not only help us match individuals with treatments that will work well for them, but would also help us identify new treatment options.
The PREDICT study is a 5-year clinical trial designed to (1) test whether clinically-relevant biomarkers can predict in advance who is most likely to benefit from prazosin for PTSD; and (2) test a working model of how pre-synaptic and post-synaptic changes in the regulation of noradrenaline may combine together to produce the symptoms of PTSD.
Project Period:
June 1, 2018 — May 31, 2023
Funding Type(s):
Federal
VA Clinical Sciences Research & Development (CSR&D)
Geographic Area(s):
Seattle/Puget Sound
Practice Type(s):
Online/remote/apps/social media, Outpatient
Patient Population(s):
Veterans
Targeted Condition(s):
PTSD
